"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 18 | 18 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 62 | 62 |
| 2006 | 1 | 57 | 58 |
| 2007 | 0 | 70 | 70 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 105 | 107 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 113 | 114 |
| 2012 | 2 | 90 | 92 |
| 2013 | 2 | 114 | 116 |
| 2014 | 0 | 130 | 130 |
| 2015 | 0 | 136 | 136 |
| 2016 | 0 | 153 | 153 |
| 2017 | 0 | 117 | 117 |
| 2018 | 0 | 143 | 143 |
| 2019 | 1 | 136 | 137 |
| 2020 | 0 | 119 | 119 |
| 2021 | 0 | 118 | 118 |
| 2022 | 0 | 41 | 41 |
| 2023 | 0 | 57 | 57 |
| 2024 | 0 | 98 | 98 |
| 2025 | 0 | 125 | 125 |
| 2026 | 0 | 74 | 74 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. Sci Adv. 2026 Aug 07; 12(32):eaeg1996.
-
Glioblastoma stem cell growth requires DOT1L-MED23 control of enhancer accessibility. Cell Rep. 2026 Jul 28; 45(7):117647.
-
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Mol Ther. 2026 Apr 01; 34(4):2154-2174.
-
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers. Nat Commun. 2026 Jan 03; 17(1):1193.
-
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition. Commun Biol. 2025 Nov 05; 8(1):1522.
-
Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress. Clin Cancer Res. 2025 Oct 15; 31(20):4345-4360.
-
TIGIT Affects CAR NK-cell Effector Function in the Solid Tumor Microenvironment by Modulating Immune Synapse Strength. Cancer Immunol Res. 2025 Oct 01; 13(10):1576-1590.
-
Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer Immunol Res. 2025 Oct 01; 13(10):1591-1608.
-
Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma. Mol Cancer Ther. 2025 Oct 01; 24(10):1640-1652.
-
Restricting metabolic plasticity enhances stress adaptation through the modulation of PDH and HIF1A in TRAP1-depleted colon cancer. Cancer Lett. 2025 Nov 01; 632:217977.